Cintas (CTAS)
(Delayed Data from NSDQ)
$695.69 USD
+3.73 (0.54%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $695.68 -0.01 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
CTAS 695.69 +3.73(0.54%)
Will CTAS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CTAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTAS
MSC Industrial (MSM) Lowers '24 View Post Preliminary Q3 Results
Has Cintas (CTAS) Outpaced Other Industrial Products Stocks This Year?
CTAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
AGCO Corp (AGCO) Declines 19% in a Year: What's Ailing the Stock?
Hudson (HDSN) Boosts Portfolio With USA Refrigerants Deal
Dover (DOV) Shares Rally 16% YTD: What's Driving the Stock?
Other News for CTAS
Cintas: Economic Profit Is Underappreciated, Not As Pricey As It Appears
IMPACT Supports, Advances and Strengthens Cintas’ LGBTQ+ Employee-Partners
Looking Into Cintas's Recent Short Interest
Cintas Named a Fortune 500 Company for the Seventh Year in a Row
Vestis: Rising Concerns Cast Shadows On Future Prospects